The IT company and famous retailer both deliver bottom-line figures that are well above analyst estimates.
The two big companies come to legal blows over allegedly faulty solar panels, while the LED lighting specialist disappoints on guidance.
The company's KeyLeaf subsidiary gets the green light to produce cannabis extracts at its Canadian facility.
The recent performance of the two related Asian tech stocks is a study in contrasts.
The bellwether marijuana stock delivered a very disappointing quarter, and Tilray's latest wasn't much better. Aurora Cannabis, meanwhile, gets to borrow a bit more money.
The addition of new lenders will give the company access to around CA$360 million.
The computer graphics card maker sees notable drops in fundamentals but still exceeds estimates, and GE's leader loads up on company stock.
Berkshire Hathaway plows some of its considerable cash pile into shares of Amazon.com, while Cisco disappoints the market.
The prominent marijuana stock trades down on news of its worse-than-expected results.
Not for the first time, America's famous tech behemoths seem to be in regulators' crosshairs; The RealReal, meanwhile, posts its first quarterly figures as a publicly traded company.
The Canadian grower and distributor posts a sharp top-line increase thanks to relatively new product categories.
The restaurant chain operator will start 2020 with a new leader, while Verizon unloads one of its well-known internet assets.
In a fresh controversy, the embattled Canadian grower is cited for a series of transgressions at its Vaughan, Ontario, facility.
Quarterly results, more quarterly results, a new buyout and a potentially new Nasdaq marijuana stock -- last week was far from boring in the cannabis industry.
The ambitious marijuana company continues to strengthen its medical cannabis business.
The ridesharing giant posts a $5 billion-plus net loss, while the two big IT companies finally sign on the dotted line.
The cannabis company more than triples its revenue figure.
Two recently estranged tech companies are apparently ready to (finally) make a deal, while Lyft delivers a pleasant upside surprise.
The company's fundamentals got a major boost from its star drug, Epidiolex.
Or, A Tale of Two Quarterly Earnings Reports.